Its anti-diabetes and obesity effects with improved lipid metabolism provide supaglutide as an alternative new tool to elucidate GLP-1 biology, seeking novel therapeutic targets for treating diabetes, obesity and its associated metabolic disorders. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.